Cargando…

A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs

AIM: To identify a potential efficacy–effectiveness gap and possible explanations (drivers of effectiveness) for differences between results of randomized controlled trials (RCTs) and observational studies investigating glucose-lowering drugs. METHODS: A systematic literature review was conducted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ankarfeldt, Mikkel Z, Adalsteinsson, Erpur, Groenwold, Rolf HH, Ali, M Sanni, Klungel, Olaf H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271378/
https://www.ncbi.nlm.nih.gov/pubmed/28176959
http://dx.doi.org/10.2147/CLEP.S121991
_version_ 1782501340309618688
author Ankarfeldt, Mikkel Z
Adalsteinsson, Erpur
Groenwold, Rolf HH
Ali, M Sanni
Klungel, Olaf H
author_facet Ankarfeldt, Mikkel Z
Adalsteinsson, Erpur
Groenwold, Rolf HH
Ali, M Sanni
Klungel, Olaf H
author_sort Ankarfeldt, Mikkel Z
collection PubMed
description AIM: To identify a potential efficacy–effectiveness gap and possible explanations (drivers of effectiveness) for differences between results of randomized controlled trials (RCTs) and observational studies investigating glucose-lowering drugs. METHODS: A systematic literature review was conducted in English language articles published between 1 January, 2000 and 31 January, 2015 describing either RCTs or observational studies comparing glucagon-like peptide-1 analogs (GLP-1) with insulin or comparing dipeptidyl peptidase-4 inhibitors (DPP-4i) with sulfonylurea, all with change in glycated hemoglobin (HbA1c) as outcome. Medline, Embase, Current Content, and Biosis were searched. Information on effect estimates, baseline characteristics of the study population, publication year, study duration, and number of patients, and for observational studies, characteristics related to confounding adjustment and selection- and information bias were extracted. RESULTS: From 312 hits, 11 RCTs and 7 observational studies comparing GLP-1 with insulin, and from 474 hits, 16 RCTs and 4 observational studies comparing DPP-4i with sulfonylurea were finally included. No differences were observed in baseline characteristics of the study populations (age, sex, body mass index, time since diagnosis of type 2 diabetes mellitus, and HbA1c) or effect sizes across study designs. Mean effect sizes ranged from −0.43 to 0.91 and from −0.80 to 1.13 in RCTs and observational studies, respectively, comparing GLP-1 with insulin, and from −0.13 to 2.70 and −0.20 to 0.30 in RCTs and observational studies, respectively, comparing DPP-4i and sulfonylurea. Generally, the identified observational studies held potential flaws with regard to confounding adjustment and selection- and information bias. CONCLUSIONS: Neither potential drivers of effectiveness nor an efficacy–effectiveness gap were identified. However, the limited number of studies and potential problems with confounding adjustment, selection- and information bias in the observational studies, may have hidden a true efficacy-effectiveness gap.
format Online
Article
Text
id pubmed-5271378
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-52713782017-02-07 A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs Ankarfeldt, Mikkel Z Adalsteinsson, Erpur Groenwold, Rolf HH Ali, M Sanni Klungel, Olaf H Clin Epidemiol Review AIM: To identify a potential efficacy–effectiveness gap and possible explanations (drivers of effectiveness) for differences between results of randomized controlled trials (RCTs) and observational studies investigating glucose-lowering drugs. METHODS: A systematic literature review was conducted in English language articles published between 1 January, 2000 and 31 January, 2015 describing either RCTs or observational studies comparing glucagon-like peptide-1 analogs (GLP-1) with insulin or comparing dipeptidyl peptidase-4 inhibitors (DPP-4i) with sulfonylurea, all with change in glycated hemoglobin (HbA1c) as outcome. Medline, Embase, Current Content, and Biosis were searched. Information on effect estimates, baseline characteristics of the study population, publication year, study duration, and number of patients, and for observational studies, characteristics related to confounding adjustment and selection- and information bias were extracted. RESULTS: From 312 hits, 11 RCTs and 7 observational studies comparing GLP-1 with insulin, and from 474 hits, 16 RCTs and 4 observational studies comparing DPP-4i with sulfonylurea were finally included. No differences were observed in baseline characteristics of the study populations (age, sex, body mass index, time since diagnosis of type 2 diabetes mellitus, and HbA1c) or effect sizes across study designs. Mean effect sizes ranged from −0.43 to 0.91 and from −0.80 to 1.13 in RCTs and observational studies, respectively, comparing GLP-1 with insulin, and from −0.13 to 2.70 and −0.20 to 0.30 in RCTs and observational studies, respectively, comparing DPP-4i and sulfonylurea. Generally, the identified observational studies held potential flaws with regard to confounding adjustment and selection- and information bias. CONCLUSIONS: Neither potential drivers of effectiveness nor an efficacy–effectiveness gap were identified. However, the limited number of studies and potential problems with confounding adjustment, selection- and information bias in the observational studies, may have hidden a true efficacy-effectiveness gap. Dove Medical Press 2017-01-23 /pmc/articles/PMC5271378/ /pubmed/28176959 http://dx.doi.org/10.2147/CLEP.S121991 Text en © 2017 Ankarfeldt et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Ankarfeldt, Mikkel Z
Adalsteinsson, Erpur
Groenwold, Rolf HH
Ali, M Sanni
Klungel, Olaf H
A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs
title A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs
title_full A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs
title_fullStr A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs
title_full_unstemmed A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs
title_short A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs
title_sort systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271378/
https://www.ncbi.nlm.nih.gov/pubmed/28176959
http://dx.doi.org/10.2147/CLEP.S121991
work_keys_str_mv AT ankarfeldtmikkelz asystematicliteraturereviewontheefficacyeffectivenessgapcomparisonofrandomizedcontrolledtrialsandobservationalstudiesofglucoseloweringdrugs
AT adalsteinssonerpur asystematicliteraturereviewontheefficacyeffectivenessgapcomparisonofrandomizedcontrolledtrialsandobservationalstudiesofglucoseloweringdrugs
AT groenwoldrolfhh asystematicliteraturereviewontheefficacyeffectivenessgapcomparisonofrandomizedcontrolledtrialsandobservationalstudiesofglucoseloweringdrugs
AT alimsanni asystematicliteraturereviewontheefficacyeffectivenessgapcomparisonofrandomizedcontrolledtrialsandobservationalstudiesofglucoseloweringdrugs
AT klungelolafh asystematicliteraturereviewontheefficacyeffectivenessgapcomparisonofrandomizedcontrolledtrialsandobservationalstudiesofglucoseloweringdrugs
AT ankarfeldtmikkelz systematicliteraturereviewontheefficacyeffectivenessgapcomparisonofrandomizedcontrolledtrialsandobservationalstudiesofglucoseloweringdrugs
AT adalsteinssonerpur systematicliteraturereviewontheefficacyeffectivenessgapcomparisonofrandomizedcontrolledtrialsandobservationalstudiesofglucoseloweringdrugs
AT groenwoldrolfhh systematicliteraturereviewontheefficacyeffectivenessgapcomparisonofrandomizedcontrolledtrialsandobservationalstudiesofglucoseloweringdrugs
AT alimsanni systematicliteraturereviewontheefficacyeffectivenessgapcomparisonofrandomizedcontrolledtrialsandobservationalstudiesofglucoseloweringdrugs
AT klungelolafh systematicliteraturereviewontheefficacyeffectivenessgapcomparisonofrandomizedcontrolledtrialsandobservationalstudiesofglucoseloweringdrugs